AsPC-1 / AsPC-1-luc Orthotopic Mouse Model Service for Pancreas Cancer

The AsPC-1 / AsPC-1-luc orthotopic mouse model grows a KRAS-mutant, metastasis-derived human pancreatic adenocarcinoma directly within the pancreatic parenchyma, reproducing the local invasion and abdominal spread typical of advanced pancreas cancer. Alfa Cytology delivers this model as a complete preclinical package — spanning authenticated reporter-cell supply, stereoscopic surgical implantation, serial in vivo bioluminescence readouts, customized dosing regimens, and terminal histopathology — built to support robust evaluation of chemotherapies, targeted agents, and emerging therapeutic modalities.

Overview of AsPC-1 / AsPC-1-luc Orthotopic Mouse Model for Pancreas Cancer

AsPC-1 is a human pancreatic adenocarcinoma cell line derived from the ascitic fluid of a 62-year-old patient and established through nude-mouse xenografts, placing it among the most aggressive and best-documented pancreas cancer lines in the NCI collection. Genetically, it carries the canonical PDAC driver constellation — mutant KRAS (G12D), inactivated TP53 with loss of p53 protein, and disrupted CDKN2A — alongside additional alterations such as MAP2K4 and, in some databases, SMAD4, GNAS, and RNF43, making it a faithful cellular proxy for late-stage, treatment-refractory disease. Its ascitic origin and poorly differentiated epithelial phenotype correlate with strong invasive behavior: in published head-to-head orthotopic comparisons, direct injection of 1×10⁶ AsPC-1 cells into the mouse pancreas produced tumors in 100% of animals, among the highest take rates of the commonly used PDAC panel.

Fig 1. Gold biodistribution analysis profile in organs and tumors of mice bearing pancreatic subcutaneous AsPC-1 tumors after treating with nanoconjugates. (Elechalawar, Chandra Kumar, et al., 2024)

The AsPC-1-luc derivative introduces stable firefly luciferase expression, converting orthotopic tumor growth into a quantifiable, non-invasive optical signal after D-luciferin administration. This enables longitudinal tracking of primary pancreatic tumor expansion, early detection of peritoneal dissemination and distant metastases, and real-time measurement of treatment response in the same cohort — advantages that have made the AsPC-1 / AsPC-1-luc orthotopic system a workhorse in in vivo studies of gemcitabine-based regimens, nab-paclitaxel combinations, stromal-targeting strategies, KRAS-pathway inhibitors, and oncolytic virotherapy.

Cell Line Information: AsPC-1 / AsPC-1-luc

The following profile consolidates the principal characteristics of AsPC-1 (ATCC CRL-1682; Cellosaurus CVCL_0152) and its luciferase-labeled derivative AsPC-1-luc, which preserves the parental genotype while adding optical reporting for in vitro assays and in vivo imaging.

Our Services

Alfa Cytology runs the AsPC-1 / AsPC-1-luc orthotopic model as a turnkey preclinical engagement. From mycoplasma-free cell expansion and luciferase signal verification through microsurgical implantation, scheduled in vivo imaging, treatment administration, and full necropsy with immunohistochemistry, every phase is documented under a defined quality framework so your team receives decision-ready data on time.

Workflow of AsPC-1 / AsPC-1-luc Orthotopic Mouse Model Construction

Construction of the AsPC-1 / AsPC-1-luc orthotopic pancreas cancer model is organized as a series of tightly controlled stages. Each step carries defined acceptance criteria to ensure reproducible engraftment and high-quality in vivo readouts.

1. Cell qualification and expansion: AsPC-1 or AsPC-1-luc cells are revived from low-passage, authenticated stocks; STR identity and mycoplasma negativity are confirmed, and cultures are scaled up in RPMI-1640 with 10% FBS to the exponential phase.
2. Luciferase confirmation (AsPC-1-luc): Reporter expression is validated in vitro by luminescence assay to guarantee uniform signal intensity prior to implantation.
3. Mouse preparation: Female immunodeficient mice (e.g., BALB/c nude or NOD/SCID, 6–8 weeks old) are acclimated, health-checked, and randomized under an approved animal-use protocol.
4. Orthotopic surgical implantation: Under anesthesia, a small left-flank or midline laparotomy exposes the pancreas; 1×10⁶–5×10⁶ AsPC-1 / AsPC-1-luc cells, optionally suspended in Matrigel, are injected into the pancreatic parenchyma or pancreatic tail using a fine needle under visual guidance, and the abdominal wall is closed in layers.
5. Recovery and baseline imaging: Animals are monitored post-operatively for wound healing and body-weight recovery; baseline bioluminescence images are then acquired after intraperitoneal D-luciferin injection to verify successful engraftment.
6. Longitudinal monitoring: Tumor burden is tracked at scheduled intervals by in vivo bioluminescence imaging, with body-weight and condition scoring recorded in parallel to flag treatment-related toxicity early.
7. Randomized dosing phase: Once tumor signals reach pre-specified thresholds, mice are randomized into vehicle and treatment groups and dosed per the study plan, with optional interim imaging or plasma sampling for pharmacodynamic markers.
8. Terminal analysis: At endpoint, primary pancreatic tumors, peritoneal deposits, and metastatic organs are harvested and weighed; ex vivo luminescence is captured, tissues are processed for H&E and immunohistochemistry (e.g., Ki67, cleaved caspase-3, α-SMA), and findings are summarized in a comprehensive study report.

Fig 2. AsPC-1 / AsPC-1-luc orthotopic mouse model construction workflow.

Case Study-AsPC-1 / AsPC-1-luc Orthotopic Mouse Model Development

Alfa Cytology has practical, ongoing experience developing and applying the AsPC-1 / AsPC-1-luc orthotopic pancreas cancer model in preclinical research settings. Work performed to date encompasses orthotopic model establishment and baseline characterization, bioluminescence-guided efficacy assessment of standard chemotherapeutics and investigational agents, and dissemination-focused study designs evaluating peritoneal and metastatic spread. All engagements are configured around each client's molecule profile and readout requirements, and further case specifics can be shared upon inquiry.

Why Choose Alfa Cytology?

For the AsPC-1 / AsPC-1-luc orthotopic pancreas cancer model, Alfa Cytology pairs surgical modeling know-how with disciplined study execution, so your program benefits from both biological fidelity and operational reliability:

• Specialized orthotopic pancreatic surgery capability with consistently high AsPC-1 engraftment rates.
• STR-verified, mycoplasma-free AsPC-1 and AsPC-1-luc cell banks with validated luciferase expression.
• Integrated in vivo bioluminescence imaging from baseline through terminal ex vivo confirmation.
• Flexible, mechanism-aware study designs spanning chemotherapy, targeted therapy, and virotherapy programs.
• Dedicated project management with transparent milestone updates and timely data delivery.
• Rigorous adherence to animal-welfare and preclinical data-quality standards at every stage.

Contact Us

Ready to move your pancreas cancer program forward with a validated AsPC-1 / AsPC-1-luc orthotopic model? Contact us for a tailored study proposal and schedule, or reach out to discuss how we can adapt this platform to your compound, biomarker, and endpoint needs — Alfa Cytology is here to help you generate the preclinical evidence your project requires.

For research use only. Not intended for any clinical use.